B
Bull
Bull · 25%PASG
$5.29
Szenariopreis
$4.520
+0.198 (+4.39%)Zum Schluss
Loading chart…
- High
- 4.600
- Open
- 4.320
- VWAP
- 4.48
- Vol
- 21.89K
- Mkt Cap
- 56.95M
- Low
- 4.310
- Amount
- 98.01K
- EV/EBITDA, TTM
- 0.00
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It also has a preclinical research program that explores multiple potential treatment targets for Huntington's disease.
AI analysis of Passage Bio Inc (PASG)
holdPassage Bio is not a good buy right now due to its significant financial losses and uncertain future. The current price is $4.52, with a year-to-date decline of 61.33% and a forward P/E ratio of 0, indicating no earnings expected in the near future. The main risk is the company's ongoing negative net income, which reached -$19.34 million in Q3 2024 and has continued to decline, leading to a current ratio of 1.22, suggesting potential liquidity issues.
Bewertungskennzahlen
The current forward P/E ratio for Passage Bio Inc (PASG) is 0.00, compared to its 5-year average forward P/E of -0.99.
Alphio AI Price Scenarios for PASG
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
8.506-26NASDAQ.COMBiotech Sector Update: FDA and EU Approvals
8.506-25NASDAQ.COMPassage Bio and Remix Therapeutics Announce Merger Agreement
2.006-25stocktwitsARS Pharmaceuticals Faces Insurance Coverage Setback
- 8.506-24stocktwits
Remix and Passage Bio Merger Details Unveiled
8.506-24seekingalphaPassage Bio and Remix Therapeutics Announce Merger Agreement
PASG FAQ — answered by Alphio AI
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It also has a preclinical research program that explores multiple potential treatment targets for Huntington's disease. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Passage Bio is not a good buy right now due to its significant financial losses and uncertain future. The current price is $4.52, with a year-to-date decline of 61.33% and a forward P/E ratio of 0, indicating no earnings expected in the near future. The main risk is the company's ongoing negative net income, which reached -$19.34 million in Q3 2024 and has continued to decline, leading to a current ratio of 1.22, suggesting potential liquidity issues.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.